• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » OmniComm Buys EDC Business, Looks for Other Acquisitions

OmniComm Buys EDC Business, Looks for Other Acquisitions

July 7, 2009
CenterWatch Staff

EClinical provider OmniComm Systems recently acquired eResearch Technology's (ERT) electronic data capture (EDC) business in a move that OmniComm executives hope will help the Fort Lauderdale, Fla.-based company become a top-tier EDC provider.

Under the terms of the agreement with ERT, OmniComm issued 8.1 million shares of common stock and assumed certain liabilities, including deferred revenue relating to ERT's EDC business in exchange for ERT's EDC software, applications and fixed assets and $1.15 million in cash paid by ERT. OmniComm also took on 16 of ERT's 20 EDC-focused employees and plans to open a new office in New Jersey, which will house the majority of the ERT support team.

The ERT acquisition is part of a larger effort by OmniComm to acquire EDC capabilities and grow its business, said OmniCommï's chief operating officer Stephen Johnson.

"We want to build a Tier 1 company," he said. "We are in full acquisition mode; we're not done. ERT is the first acquisition, but we're looking at several others right now. We're going out there and trying to find the best technologies to fuse or integrate with our technologies to give our customers the best portfolio of products."

ERT's EDC platform provides OmniComm with additional clinical trial management system (CTMS) functionality, as well as enhanced reporting and data management system capabilities. The company plans to add these capabilities to its existing EDC software to create a version of the software that includes the best of both companies' capabilities. The ERT deal--and the fact that OmniComm can roll the two companies' capabilities into one product--is just the type of acquisition that OmniComm is looking to make, Johnson said.

"We're not looking to add complementary products, like add a safety system and add a CTMS system and add a clinical data management system to our EDC portfolio. We want to stay focused on EDC," Johnson said. "What we will do is add complementary functionality."

In addition to its complementary capabilities, ERT's EDC system was attractive to OmniComm because of its customers--most of whom license the EDC software to use on their existing trials. This is the opposite of OmniComm's customer base, which is mostly on the host services side.

"We think that the recipe for being a stable financial organization with predictable revenue streams is to have a good mix of hosted services deals and license deals," Johnson said.

Based in Philadelphia, ERT has traditionally been a provider of cardiac safety technology and plans to focus on that core business line going forward, according to a company statement.

ERT's EDC division brought in $5.9 million in revenues for the company in 2008 (ERT's total net revenues for 2008 were $133 million), and the company reported revenues of $1.4 million for its EDC division in the first quarter of 2009. OmniComm plans to see similar revenues for the EDC unit out of the gate, Johnson said, but the real payoff will occur when OmniComm releases a new version of its EDC software, incorporating ERT's capabilities.

"When we come out with the combined energies of both products, we think that we're going to grow the market share on both sides of the fence. This hybrid release that we're going to come out with in the future, we think it's going to be the industry standard," he said.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing